Log In
BCIQ
Print this Print this
 

SIT-1007

  Manage Alerts
Collapse Summary General Information
Company SialoTec GmbH
DescriptionCD22 ligand based targeted therapy
Molecular Target CD22
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today